Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Dermal Hypersensitivity Reaction
NCT06012448Phase 4Completed
- Sponsor
- University of Michigan
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in dermal hypersensitivity reaction (DHR), sponsored by University of Michigan. Started Oct 2023; status: completed.
02
Drugs
03
Conditions
dermal hypersensitivity reaction (DHR)
Beyond the preview
Go deeper on NCT06012448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012448.